- Home
- DMAC vs DSM Comparison
DMAC vs DSM Comparison
Compare DMAC & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- DSM
- Stock Information
- Founded
- DMAC 2000
- DSM 1989
- Country
- DMAC United States
- DSM United States
- Employees
- DMAC N/A
- DSM N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- DSM Investment Managers
- Sector
- DMAC Health Care
- DSM Finance
- Exchange
- DMAC Nasdaq
- DSM Nasdaq
- Market Cap
- DMAC 310.1M
- DSM 304.0M
- IPO Year
- DMAC N/A
- DSM N/A
- Fundamental
- Price
- DMAC $6.70
- DSM $6.02
- Analyst Decision
- DMAC Strong Buy
- DSM
- Analyst Count
- DMAC 3
- DSM 0
- Target Price
- DMAC $12.33
- DSM N/A
- AVG Volume (30 Days)
- DMAC 256.1K
- DSM 161.7K
- Earning Date
- DMAC 11-12-2025
- DSM 01-01-0001
- Dividend Yield
- DMAC N/A
- DSM 3.97%
- EPS Growth
- DMAC N/A
- DSM N/A
- EPS
- DMAC N/A
- DSM N/A
- Revenue
- DMAC N/A
- DSM N/A
- Revenue This Year
- DMAC N/A
- DSM N/A
- Revenue Next Year
- DMAC N/A
- DSM N/A
- P/E Ratio
- DMAC N/A
- DSM N/A
- Revenue Growth
- DMAC N/A
- DSM N/A
- 52 Week Low
- DMAC $3.19
- DSM $4.69
- 52 Week High
- DMAC $7.49
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- DMAC 48.84
- DSM 59.37
- Support Level
- DMAC $6.50
- DSM $5.93
- Resistance Level
- DMAC $7.10
- DSM $6.07
- Average True Range (ATR)
- DMAC 0.29
- DSM 0.05
- MACD
- DMAC -0.03
- DSM -0.00
- Stochastic Oscillator
- DMAC 32.90
- DSM 64.29
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.